Clinical trial
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene…
NCT03375164 · Sarepta Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT03375164 |
|---|---|
| Title | A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) |
| Official title | Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001) |
| Lead sponsor | Sarepta Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention type | Genetic |
| Interventions | delandistrogene moxeparvovec |
| Enrollment | 4 |
| Start date | Jan 4, 2018 |
| Primary completion | Apr 25, 2023 |
| Completion | Apr 25, 2023 |
| First posted | Dec 15, 2017 |
| Last update posted | Nov 14, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: